The University of Pittsburgh Cancer Institute (UPCI) proposes to conduct a Specialized Program of Research Excellence (SPORE) in Lung Cancer. The overall goals of the UPCI Lung Cancer SPORE are to improve detection and treatment of lung cancer and to understand the mechanisms of increased susceptibility of women to lung cancer. The SPORE program will consist of five major translational research projects in lung cancer, three research cores, an administrative core, a developmental research program, and a career development program. The UPCI Lung Cancer SPORE will use an interdisciplinary approach to meet its objectives by carrying out projects with co-investigators in basic, applied and clinical science. It is also organ-specific in its approach and all projects will test hypotheses about lung cancer biology, susceptibility, detection, or treatment. The long-term goal of the UPCI SPORE is to conduct clinical trials based on research results from its translational research projects that will serve as the basis for improving the outcome of patients diagnosed with lung cancer. The five main projects are: (1) Expression of Gastrin-Releasing Peptide Receptor as a Risk Factor for Lung Cancer; (2) Role of Estrogens in the Development of Lung Cancer; (3) Cyclin B1 as a Non-Small Lung Tumor Antigen; (4) Protection of Esophagus and Normal Lung from Chemoradiotherapy Damage with Radiosensitization of Tumor in Non-Small Cell Lung Cancer by Manganese Superoxide Distmutase-Plasmid Liposome Gene Therapy; (5) Molecular Epidemiology of CT-Detected Lung Cancer. The three research cores will assist the main research projects, developmental research projects, and career development investigators in carrying out lung cancer translational research. The research cores are Tissue and Genomics Core, and Biostatistics Core. The administrative core will provide scientific and fiscal oversight for the program. UPCI SPORE investigators will work together as a team to meet the goals of the program and will also interact with investigators from Lung Cancer SPORES at other institutions to improve outcome for lung cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090440-02
Application #
6514963
Study Section
Special Emphasis Panel (ZCA1-GRB-V (J1))
Program Officer
Ujhazy, Peter
Project Start
2001-06-01
Project End
2006-04-30
Budget Start
2002-05-01
Budget End
2003-04-30
Support Year
2
Fiscal Year
2002
Total Cost
$2,579,831
Indirect Cost
Name
University of Pittsburgh
Department
Pharmacology
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Leng, Shuguang; Diergaarde, Brenda; Picchi, Maria A et al. (2018) Gene Promoter Hypermethylation Detected in Sputum Predicts FEV1 Decline and All-Cause Mortality in Smokers. Am J Respir Crit Care Med 198:187-196
Rothenberger, Natalie J; Somasundaram, Ashwin; Stabile, Laura P (2018) The Role of the Estrogen Pathway in the Tumor Microenvironment. Int J Mol Sci 19:
Yochum, Zachary A; Cades, Jessica; Wang, Hailun et al. (2018) Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene :
Stabile, Laura P; Farooqui, Mariya; Kanterewicz, Beatriz et al. (2018) Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer. J Thorac Oncol 13:399-412
Volonte, Daniela; Vyas, Avani R; Chen, Chen et al. (2018) Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence. J Biol Chem 293:1794-1809
Hopkins, Kathleen G; Ferson, Peter F; Shende, Manisha R et al. (2017) Prospective study of quality of life after lung cancer resection. Ann Transl Med 5:204
Vendetti, Frank P; Leibowitz, Brian J; Barnes, Jennifer et al. (2017) Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation. Sci Rep 7:41892
Tarhini, Ahmad A; Rafique, Imran; Floros, Theofanis et al. (2017) Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer 123:2936-2944
Sun, Fan; Xiao, Gutian; Qu, Zhaoxia (2017) Isolation of Murine Alveolar Type II Epithelial Cells. Bio Protoc 7:
Dandachi, Nadine; Kelly, Neil J; Wood, John P et al. (2017) Macrophage Elastase Induces TRAIL-mediated Tumor Cell Death through Its Carboxy-Terminal Domain. Am J Respir Crit Care Med 196:353-363

Showing the most recent 10 out of 191 publications